Chronic Hepatitis B Market Report 2026

Chronic Hepatitis B Market Overview

• Chronic Hepatitis B market size has reached to $3.93 billion in 2025 • Expected to grow to $4.74 billion in 2030 at a compound annual growth rate (CAGR) of 3.7% • Growth Driver: High Prevalence Of Hepatitis B Infection • Market Trend: Major Companies Innovate In Chronic Hepatitis B Treatment With Novel Antiviral Therapies And Clinical Trials • North America was the largest region in 2025.

What Is Covered Under Chronic Hepatitis B Market?

Chronic hepatitis B is a long-term infection with the hepatitis B virus (HBV) lasting over six months, potentially leading to severe liver damage, liver failure, or liver cancer. It is often asymptomatic for years but can be detected through blood tests and managed with antiviral medications and regular monitoring. The main types of drugs in chronic hepatitis B include antivirals and immunomodulators. Antivirals are medications designed to inhibit the growth and replication of viruses and help manage the chronic hepatitis B condition by reducing the viral load in the liver and slowing liver damage progression. The gender types include male and female, and the distribution channels include hospital pharmacies, drug stores and retail pharmacies, and online providers.

What Is The Chronic Hepatitis B Market Growth Forecast?

The chronic hepatitis b market size is expected to see steady growth in the next few years. It will grow to $4.74 billion in 2030 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to increasing investments in next-generation HBV therapies, rising demand for finite-duration treatment regimens, expansion of therapeutic vaccine development, growing focus on eliminating viral reservoirs, increased global hepatitis elimination initiatives. Major trends in the forecast period include increasing adoption of long-term antiviral therapies, rising development of functional cure approaches, growing focus on early disease detection and monitoring, expansion of immune-modulating treatment strategies, enhanced patient adherence programs.

Global Chronic Hepatitis B Market Segmentation

1) By Drug Class: Antivirals, Immune Modulators 2) By Gender: Male, Female 3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers Subsegments: 1) By Antivirals: Nucleos(T) Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon) 2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)

What Is The Driver Of The Chronic Hepatitis B Market?

The high prevalence of chronic hepatitis B infection is expected to propel the growth of the chronic hepatitis B virus market going forward. Hepatitis B is a liver infection brought on by the hepatitis B virus (HBV), which is prevented through vaccination. The increase in hepatitis B infection rates is due to a combination of factors, particularly in low- and middle-income countries, due to low vaccination coverage leading to higher transmission rates as large portions of the population remain unprotected. Rising hepatitis B infection rates can increase demand for diagnostic tests and treatment options. For instance, in June 2024, according to a report published by the Centers for Disease Control and Prevention (CDC), a US-based government agency, increasing global hepatitis B vaccination coverage to 90% and treatment access to 80% could prevent 26 million new infections and 9 million deaths attributable to hepatitis B between 2022 and 2050. In 2022, there were 1.2 million new cases of hepatitis B virus (HBV) infection. Therefore, the high prevalence of hepatitis B infection will drive the chronic hepatitis B virus market.

Key Players In The Global Chronic Hepatitis B Market

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

Global Chronic Hepatitis B Market Trends and Insights

Major companies operating in the chronic hepatitis B market are focusing on technological advancements such as novel antiviral therapies. Novel antiviral therapies are innovative medications targeting viral infections, especially resistant ones, by inhibiting replication and using advanced delivery systems, with ongoing clinical trials for safety and effectiveness, such as bepirovirsen for chronic hepatitis B. For instance, in February 2024, GSK plc, a UK-based multinational pharmaceutical and biotechnology company that specializes in the research, development, manufacturing, and marketing of a wide range of healthcare products, received the U.S. Food and Drug Administration (FDA) Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB). Bepirovirsen is designed to target and degrade the RNA of the hepatitis B virus (HBV), potentially allowing the immune system to regain control over the infection. The drug has demonstrated promising results in Phase IIb trials, specifically the B-Clear and B-Sure studies, where it showed efficacy in reducing hepatitis B surface antigen (HBsAg) levels and achieving sustained viral suppression.

What Are Latest Mergers And Acquisitions In The Chronic Hepatitis B Market?

In November 2023, GSK plc, a U.K.-based pharmaceuticals company, acquired exclusive rights to hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. With the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug, GSK aims to expand its portfolio and strengthen its position in the treatment of chronic hepatitis B by adding a new, potentially valuable therapy to its offerings. Janssen Pharmaceuticals, a Belgium-based subsidiary of Johnson & Johnson, specializes in developing treatments for various serious and complex diseases, including infectious diseases such as chronic hepatitis B.

Regional Outlook

North America was the largest region in the chronic hepatitis B market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chronic Hepatitis B Market?

The chronic hepatitis B market consists of revenues earned by entities by providing services such as diagnostic testing, treatments, liver function monitoring, patient education, and support programs.The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic hepatitis B market also includes sales of medications, interferons, liver transplant medications, diagnostic kits, liver biopsy equipment, and HBV vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Hepatitis B Market Report 2026?

The chronic hepatitis b market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic hepatitis b industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.